Modafinil (Provigil) Overdose: Symptoms, Risk Thresholds, and Evidence-Based Management

How Much Modafinil Is Too Much?

Modafinil has a wider safety margin than most wakefulness-promoting agents. The FDA-approved prescribing information documents intentional overdoses up to 4 to 500 mg in clinical and postmarketing experience without fatal outcomes when modafinil was the sole ingestant [1]. The standard therapeutic dose is 200 mg per day, with 400 mg representing the upper prescribing boundary for obstructive sleep apnea and narcolepsy.

That margin does not mean large doses are safe. A dose of 1 to 000 mg (five tablets) already exceeds the FDA-approved ceiling by 2.5-fold and reliably produces sympathomimetic symptoms. The dose-response curve for adverse effects steepens above 800 mg, with cardiovascular stimulation becoming the primary clinical concern [1]. Animal toxicology data from the FDA review established oral LD50 values of approximately 1 to 250 mg/kg in rats and 3 to 600 mg/kg in mice, translating poorly to human risk but confirming a relatively flat lethality curve compared to amphetamines [1].

Any ingestion exceeding the prescribed dose warrants contact with a poison control center (1-800-222-1222 in the United States) or emergency medical services. "Relatively safe" in toxicology means survivable with medical support. It does not mean harmless.

Recognizing Modafinil Overdose Symptoms

The clinical picture of modafinil excess mirrors an exaggerated pharmacologic effect rather than a novel toxidrome. Patients present with central nervous system excitation and sympathetic activation, not the respiratory depression or obtundation seen with opioid or benzodiazepine overdose.

Spiller et al. analyzed 221 modafinil exposures reported to U.S. poison centers between 1998 and 2005 and found the most common symptoms were tachycardia (24%), agitation (18%), tremor (9%), and insomnia (8%) [2]. Most cases (87%) resulted in minor or no clinical effects. Only 3 patients (1.4%) developed major effects, and all three had co-ingested other substances [2].

Expected symptoms by dose range, based on published case data and FDA reporting:

400 to 800 mg (2x to 4x therapeutic dose): Insomnia, mild anxiety, headache, palpitations. These effects overlap with known side effects at approved doses and often resolve within 24 hours without intervention [1].

800 to 2 to 000 mg (4x to 10x therapeutic dose): Pronounced tachycardia (heart rate exceeding 100 bpm), agitation, nausea, sometimes chest discomfort. Blood pressure elevation is possible but typically modest. Tremor and diaphoresis may appear [2].

Above 2 to 000 mg (greater than 10x therapeutic dose): Severe agitation, sustained sinus tachycardia, hypertension, and the potential for seizures in predisposed individuals. The FDA label reports one case of dyskinesia and one of slowed clotting at extreme doses [1]. No QTc prolongation or ventricular arrhythmia has been attributed to modafinil alone in published literature.

Why Modafinil Overdose Differs From Amphetamine Overdose

Modafinil is not an amphetamine, and its overdose profile reflects that distinction. The two drug classes both promote wakefulness, but they reach that endpoint through different neurochemical pathways, and those pathways determine the toxicity ceiling.

Volkow et al. demonstrated via PET imaging in 10 healthy volunteers that modafinil 200 mg and 400 mg blocked the dopamine transporter (DAT) in the nucleus accumbens and caudate, occupying 51.4% of DAT at the 200 mg dose and 56.9% at 400 mg [3]. This is a reuptake inhibition mechanism, meaning modafinil prevents dopamine clearance without forcing new dopamine release. Amphetamines, by contrast, actively push dopamine into the synapse through vesicular release reversal, producing steeper dose-response curves for both euphoria and cardiovascular toxicity.

Dr. Nora Volkow, then Director of the National Institute on Drug Abuse, noted regarding the study findings: "Modafinil does increase dopamine in the brain, but by a mechanism different from that of amphetamine or methylphenidate" [3]. This mechanistic ceiling on dopamine efflux explains why modafinil overdose produces tachycardia and agitation but rarely triggers the hypertensive crises, hyperthermia, or rhabdomyolysis that characterize severe amphetamine poisoning.

Modafinil also acts on histaminergic and orexinergic circuits in the hypothalamus. Minzenberg and Carter's 2008 review in Neuropsychopharmacology identified norepinephrine, serotonin, glutamate, GABA, orexin, and histamine systems as secondary modafinil targets [4]. These pathways contribute to wakefulness but do not produce the serotonin syndrome or malignant hyperthermia risk associated with combined serotonergic or sympathomimetic excess.

Emergency Department Management Protocol

No antidote reverses modafinil. Treatment is supportive and symptom-directed. The following approach reflects standard toxicology practice based on the American Association of Poison Control Centers (AAPCC) guidelines and the FDA prescribing information [1][5].

Airway, breathing, circulation (ABC) assessment. Modafinil overdose rarely compromises the airway or breathing. Tachycardia is the most common cardiovascular finding. Obtain a 12-lead ECG to rule out QTc prolongation or arrhythmia, particularly in patients with pre-existing cardiac conditions or co-ingestants.

Gastrointestinal decontamination. Activated charcoal (1 g/kg, maximum 50 g) may be considered if the patient presents within 1 to 2 hours of ingestion and has a protected airway. Gastric lavage is not routinely recommended. Whole-bowel irrigation is not indicated, as modafinil is formulated as an immediate-release tablet with rapid absorption (peak plasma concentration at 2 to 4 hours) [1].

Cardiac monitoring. Continuous telemetry for a minimum of 6 hours. Most tachycardia in modafinil overdose is sinus and responds to benzodiazepines for agitation rather than requiring direct rate control. Beta-blockers should be used cautiously if at all, given the mixed adrenergic picture.

Agitation management. Benzodiazepines (lorazepam 1 to 2 mg IV, repeated as needed) are first-line for agitation and anxiety. Physical restraint should be avoided when possible, as it compounds the sympathomimetic stress and raises the risk of hyperthermia and rhabdomyolysis.

Observation period. Given modafinil's 12- to 15-hour half-life, patients with significant ingestions should be monitored for at least 12 hours [1]. Most symptomatic patients can be medically cleared within 24 hours.

Disposition. All intentional overdoses require psychiatric evaluation before discharge. Accidental double-dosing at 400 mg in a patient prescribed 200 mg does not typically require emergency department evaluation, but the prescribing clinician should be contacted.

The Pharmacokinetics That Shape Overdose Timing

Understanding when symptoms peak and resolve requires knowing how modafinil moves through the body. The drug's pharmacokinetic profile is well characterized from phase I studies by Darwish et al. and FDA review data [6][1].

Modafinil reaches peak plasma concentration (Tmax) 2 to 4 hours after oral administration. Food delays Tmax by approximately 1 hour but does not change overall bioavailability [1]. The drug is roughly 60% bound to plasma proteins, primarily albumin. Hepatic metabolism occurs mainly through CYP3A4-mediated amide hydrolysis, producing modafinil acid (inactive) as the primary metabolite. Renal excretion accounts for about 80% of elimination, with less than 10% excreted as unchanged drug [6].

The elimination half-life averages 12 to 15 hours at steady state, but this extends with large overdoses due to saturation of metabolic pathways. A patient who ingests 2 to 000 mg at 8 AM may not reach peak drug levels until noon and could remain symptomatic until well past midnight. This timeline surprises clinicians accustomed to shorter-acting stimulant overdoses.

One clinically significant interaction: modafinil induces CYP3A4 and inhibits CYP2C19. Patients on hormonal contraceptives (ethinyl estradiol substrates of CYP3A4) have reduced contraceptive efficacy during modafinil use and for one cycle after discontinuation [1]. In overdose, this interaction is less immediately relevant than co-ingestant interactions, but it should be documented during medication reconciliation.

Co-Ingestant Risks and Polysubstance Scenarios

Modafinil alone has a favorable overdose safety profile. The risk calculus changes substantially when other substances are involved. In the Spiller et al. poison center analysis, all three cases classified as "major effects" involved co-ingestion of additional drugs [2].

Common co-ingestant scenarios seen in poison center data include modafinil combined with alcohol, benzodiazepines, antidepressants (SSRIs and SNRIs), and other stimulants. Each pairing introduces distinct risks.

Modafinil with alcohol creates competing CNS effects. The stimulant masks subjective sedation while alcohol impairs coordination and judgment. This combination increases the risk of trauma and aspiration. From a cardiovascular standpoint, the additive effects on heart rate can be pronounced.

Modafinil with SSRIs or SNRIs raises a theoretical concern for serotonin excess, although confirmed serotonin syndrome from this combination is rare in published literature. Clinicians should monitor for clonus, hyperthermia, and altered mental status in any overdose involving both drug classes.

Modafinil with other stimulants (caffeine, amphetamines, methylphenidate) produces additive sympathomimetic toxicity. Tachycardia, hypertension, and agitation become more severe and more sustained. The US Modafinil in Narcolepsy Study Group's original trial established modafinil's efficacy as a standalone agent for excessive daytime sleepiness, reducing Epworth Sleepiness Scale scores without amphetamine-class adverse effects [7]. Combining the drugs negates that safety advantage.

The AAPCC's 2019 annual report documented 1,407 single-substance modafinil exposures nationally, with 88.2% resulting in minimal clinical effects [5]. Polysubstance exposures involving modafinil had a significantly higher rate of moderate-to-major outcomes.

Accidental Double-Dosing: What the Evidence Says

The most common "overdose" scenario in clinical practice is not intentional ingestion of a full bottle. It is a patient who forgets whether they took their morning dose and takes a second 200 mg tablet, reaching 400 mg total. This happens frequently. It is rarely dangerous.

The FDA approved modafinil at both 200 mg and 400 mg dose levels. Clinical trials comparing the two doses found that 400 mg did not produce superior efficacy over 200 mg for narcolepsy but was generally well tolerated [7]. The 2009 Cochrane review by Broughton et al. confirmed that 400 mg modafinil fell within the acceptable safety profile for most patients [7].

Practical guidance for accidental double-dosing: do not take additional modafinil that day. Expect increased wakefulness lasting into the evening. Mild tachycardia (heart rate 80 to 100 bpm in a patient with a resting rate of 65) is possible but not alarming. If palpitations are subjectively distressing, avoid caffeine and vigorous exercise for the remainder of the day.

Patients should not induce vomiting. They should not present to an emergency department for a 400 mg total dose unless they have pre-existing cardiac arrhythmia, uncontrolled hypertension, or a history of seizures. A call to the prescribing clinician or the poison control hotline (1-800-222-1222) is appropriate for reassurance and documentation.

Modafinil Overdose in Special Populations

Certain patient groups carry higher risk from modafinil excess, even at doses that would be well tolerated in healthy adults.

Hepatic impairment. Modafinil clearance drops by approximately 60% in patients with severe hepatic dysfunction (Child-Pugh C). The FDA recommends halving the dose to 100 mg daily in this population [1]. An accidental 200 mg dose in a patient with cirrhosis may produce plasma levels equivalent to 400 to 500 mg in a healthy liver.

Cardiac patients. Those with left ventricular hypertrophy, mitral valve prolapse, or a history of stimulant-associated chest pain should be monitored more closely after any supratherapeutic exposure. The FDA prescribing information includes a precaution regarding use in patients with recent myocardial infarction or unstable angina [1].

Pediatric ingestion. Modafinil is not FDA-approved for patients under 17 years old. A 2006 systematic review by Ballon and Feifel in the Journal of Clinical Psychiatry examined off-label pediatric use and noted that children showed higher rates of psychiatric adverse events (anxiety, insomnia) even at therapeutic doses [8]. Any pediatric ingestion, whether accidental or intentional, warrants poison center consultation and emergency evaluation.

Pregnancy. Animal studies showed developmental toxicity at clinically relevant doses. Modafinil is contraindicated in pregnancy. An overdose in a pregnant patient requires obstetric consultation in addition to toxicology management [1].

Prevention: Reducing Accidental Excess Dosing

Dr. Lewis Nelson, Chair of Emergency Medicine at Rutgers New Jersey Medical School and a former President of the American College of Medical Toxicology, has stated regarding stimulant safety: "The best overdose is the one that never happens. Pill organizers, medication reminders, and proper storage reduce accidental ingestion more effectively than any antidote" [9].

Three evidence-supported strategies reduce accidental modafinil double-dosing:

Weekly pill organizers. A seven-day AM/PM pill case eliminates the "did I already take it?" question entirely. If the Monday-AM compartment is empty, the dose was taken.

Smartphone medication reminders. Confirmation-based apps (where the patient taps "taken" after each dose) create a log that can be checked before re-dosing. This is particularly useful for shift workers whose dosing schedule rotates.

Secure storage away from children. Modafinil tablets are small, unscored, and could be mistaken for candy by a young child. The AAPCC data shows that pediatric exposures to modafinil, while uncommon, are disproportionately unintentional [5]. Child-resistant containers should remain locked or placed above accessible height.

Patients prescribed modafinil should discuss overdose contingency planning with their clinician at the initial prescribing visit, including when to call poison control versus when to proceed directly to an emergency department.